Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
Authors:
- Edward J. KimEKEdward J. Kim
Open Access
- 20 November 2012
- journal article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 5 (3) , 622-626
Abstract
Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease stability. More recently, sunitinib and everolimus have been approved for advanced stage PNETs based on a survival benefit. However, both agents have a <10% actual response rate and cause nontrivial side effect profiles that limit duration of therapy. In locally advanced disease, there is a paucity of data to support an optimal neoadjuvant approach with the expectation of down-staging to allow for curative resection. We describe in this case a young woman who was successfully down-staged using a chemotherapy regimen of capecitabine and temozolomide with minimal toxicity.Keywords
This publication has 10 references indexed in Scilit:
- Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An UpdateJournal of the National Comprehensive Cancer Network, 2012
- Everolimus for Advanced Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 2010
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study GroupJournal of Clinical Oncology, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survivalAnnals of Oncology, 2008
- Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective reviewJournal of Clinical Oncology, 2006
- Effective treatment of neuroendocrine tumors With temozolomide and capecitabineJournal of Clinical Oncology, 2005